{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"44.6","upperLimit":"73.1","value":"59.5"},{"groupId":"OG001","lowerLimit":"35.0","upperLimit":"86.5","value":"63.6"},{"groupId":"OG002","lowerLimit":"24.9","upperLimit":"98.7","value":"75.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"The percentage of participants who experienced grade 3 or higher adverse event based on the Common Toxicity Criteria for Adverse Events Version 4.0 (CTCAEv4).","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG000","title":"[Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Colorectal)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly","id":"OG001","title":"Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Ovarian)"},{"description":"Participants received pembrolizumab 200 mg administered intravenously every 3 weeks in combination with trebananib administered intravenously at 30 mg/kg weekly.","id":"OG002","title":"Dose Expansion Dose Level II] Pembrolizumab + Trebananib (Renal Cell Carcinoma)"}],"paramType":"NUMBER","populationDescription":"This analysis only included participants enrolled and treated during the dose expansion period.","reportingStatus":"POSTED","timeFrame":"The median follow up time was 3.3 months (range: 0.6 to 25.3 months).","title":"Grade 3 or Higher Toxicity Rate in Expansion Cohort","type":"PRIMARY","unitOfMeasure":"percentage of participants"}